Literature DB >> 9256889

Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy.

H K Kim1, A F Thornton, H S Greenberg, M A Page, L Junck, H M Sandler.   

Abstract

We evaluated the potential of three-dimensional conformal therapy for re-irradiation of selected intracranial neoplasms and reviewed the retreatment of 20 patients at the University of Michigan between May 1988 and August 1991. All patients had previously undergone a full course of external beam radiotherapy (RT) to a median dose of 5,940 cGy (range 5,100-6,500 cGy), including five whole brain treatments. All recurrences were unsuitable for brachytherapy or radiosurgery. Various histologies were retreated, including 14 high-grade gliomas. Median time to re-irradiation was 38 months (range 9 months to 19 years, 6 months). RT was delivered with complex plans designed using fully integrated computed tomography/magnetic resonance imaging (CT/ MRI) tumor volume information, and regions of previous parenchymal treatment were avoided if possible. Composite (initial+retreatment) dose-volume histograms (DVH) of dose to nontarget brain allowed comparison of alternative plans to select beam orientations which minimized normal brain irradiation. Mean target dose of re-irradiation was 3,600 cGy (range 3,060-5,940 cGy). Total cumulative dose ranged from 8,060 to 11,940 cGy. Median survival was 9 months, and 1-year actuarial survival was 26%. After retreatment, 8 of 12 patients (67%) had steroid dose decrement and neurologic improvement at 4-48 months (median duration 14 months). Radiographic regression or stabilization of disease was noted in 11 of 16 patients (68%). Re-irradiation with highly conformal three-dimensional planning provides frequent clinical improvement with acceptable morbidity and should be considered in selected patients with recurrent intracranial neoplasms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256889     DOI: 10.1097/00000421-199708000-00007

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Authors:  Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

Review 2.  External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma.

Authors:  Neil K Taunk; Fabio Y Moraes; Freddy E Escorcia; Lucas Castro Mendez; Kathryn Beal; Gustavo N Marta
Journal:  Expert Rev Anticancer Ther       Date:  2016-02-09       Impact factor: 4.512

3.  Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry.

Authors:  Ali M Saeed; Rahul Khairnar; Ankur M Sharma; Gary L Larson; Henry K Tsai; Chiachien J Wang; Lia M Halasz; Prakash Chinnaiyan; Carlos E Vargas; Mark V Mishra
Journal:  Adv Radiat Oncol       Date:  2020-04-22

4.  The effect of sequential radiochemotherapy in preirradiated malignant gliomas in a phase II study.

Authors:  Ulrich Schäfer; Oliver Micke; Patrick Schüller; Andreas Schuck; Normann Willich
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

5.  Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm.

Authors:  Eleftherios Archavlis; Nikolaos Tselis; Gerhard Birn; Peter Ulrich; Nikolaos Zamboglou
Journal:  J Neurooncol       Date:  2014-06-20       Impact factor: 4.130

6.  Hypofractionated reirradiation for recurrent malignant glioma.

Authors:  Guido Henke; Frank Paulsen; Joachim P Steinbach; Ute Ganswindt; Hana Isijanov; Rolf-Dieter Kortmann; Michael Bamberg; Claus Belka
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

7.  Modern reirradiation for recurrent gliomas can safely delay tumor progression.

Authors:  Ryan S Youland; John Y Lee; Cole R Kreofsky; Paul D Brown; Joon H Uhm; Nadia N Laack
Journal:  Neurooncol Pract       Date:  2017-06-15

Review 8.  Recurrent malignant glioma in adults.

Authors:  Stephen B Tatter
Journal:  Curr Treat Options Oncol       Date:  2002-12

9.  External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain.

Authors:  Peter Sminia; Ramona Mayer
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

10.  A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG).

Authors:  Maurizio Amichetti; Dante Amelio
Journal:  Cancers (Basel)       Date:  2011-10-28       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.